Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction
Portfolio Pulse from
Veru announced positive results from its Phase 2b QUALITY clinical study, showing that Enobosarm significantly reduced lean mass loss in patients using WEGOVY for weight reduction. The study met its primary endpoint, with Enobosarm users losing 71% less lean mass compared to those on WEGOVY alone.
January 27, 2025 | 11:45 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Veru's Enobosarm showed positive results in reducing lean mass loss in patients using WEGOVY, meeting the primary endpoint in a Phase 2b study.
The positive results from the Phase 2b study are likely to boost investor confidence in Veru's product pipeline, potentially leading to a short-term increase in stock price. The study's success in meeting its primary endpoint is a significant milestone for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100